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Abstract: 24	
We have developed a transencapsidated vaccine delivery system based on 25	
the insect virus, Flock House virus (FHV). FHV is attractive due to its small 26	
genome size, simple organization, and non-pathogenic characteristics. With 27	
the insertion of a Tobacco mosaic virus (TMV) origin of assembly (Oa), the 28	
independently replicating FHV RNA1 can be transencapsidated by TMV coat 29	
protein. In this study we demonstrated that the Oa adapted FHV RNA1 30	
transencapsidation process can take place in planta, by using a bipartite plant 31	
expression vector system, where TMV coat protein is expressed by another 32	
plant virus vector, Foxtail mosaic virus (FoMV). Dual infection in the same cell 33	
by both FHV and FoMV was observed. Though an apparent classical coat-34	
protein-mediated resistance repressed FHV expression, this was overcome 35	
by delaying inoculation of the TMV coat protein vector by three days after 36	
FHV vector inoculation. Expression of transgene marker in animals by these 37	
in vivo generated transencapsidated nanoparticles was confirmed by mouse 38	
vaccination, which also showed an improved vaccine response compared to 39	
similar in vitro produced vaccines.  40	
 41	
 42	
 43	
 44	
 45	
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Introduction 46	
Virus-based nanoparticles have been extensively explored as a vaccine 47	
delivery strategy due to their typically higher immunogenicity compared with 48	
unassembled vaccine antigens (1, 2), their potential to serve as their own 49	
adjuvant (1-3), and their greater safety and potentially relatively lower cost of 50	
protection compared to traditional vaccines(4). Virus-like particles (VLPs) 51	
display vaccine antigen on their surface and can be produced by the self-52	
assembly of viral coat protein subunits expressed in a heterologous host, 53	
such as bacteria (5) or plants (6), or in mammalian cells (7). An alternative to 54	
VLPs is to use viral coat protein to encapsidate the RNA of another virus, with 55	
the RNA expressing the vaccine antigen once delivered to the target cell. In 56	
this way, the viral RNA can be packaged in an especially resistant 57	
nanoparticle similar to a VLP. The potential advantage of this strategy over 58	
VLPs is the activation of innate immunity by viral replication (8-10). 59	
 60	
Among numerous trials using viral nanoparticles for antigen delivery, Tobacco 61	
mosaic virus (TMV) nanoparticles seem to hold special promise. TMV virions 62	
are characterized by great stability and low cost production (11), and a recent 63	
study suggests that the human population has already been extensively 64	
exposed to TMV coat antigen through exposure to food and tobacco sources 65	
(12). Furthermore, extensive data show that pre-existing immunity to TMV 66	
coat does not disrupt boosting of either cytotoxic T lymphocyte (CTL, (13, 14) 67	
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or antibody target antigens (15, 16). Lastly, TMV virions are extremely stable, 68	
remaining infective for over a century at room temperature (17). TMV exhibits 69	
robust expression in plants at up to 5-10% dry weight, and is easy to purify at 70	
the commercial scale (11).  71	
 72	
Consequently, TMV nanoparticles have been explored as a VLP epitope 73	
platform. The highly uniform repeated organization of 2130 copies of coat 74	
protein subunits and the associated strong cross-linking pattern provide 75	
greatly improved efficacy to deliver antigens to antigen presenting cells. 76	
Various studies have validated that TMV-antigen conjugation can induce B 77	
cell activation and raised antibody titers (15, 18, 19), even when the 78	
conjugates are poorly immunogenic, such as carbohydrates (20). 79	
Furthermore, TMV uptake by dendritic cells is rapid and efficient (14, 18), and 80	
peptide-presenting TMV nanoparticles were proven to be able to elicit T cell 81	
responses with augmented interferon gamma (IFNγ) levels (14). We have 82	
also previously successfully tested ovalbumin-conjugated TMV vaccines, as 83	
well as a bivalent TMV vaccine displaying both mouse melanoma-associated 84	
CTL epitopes p15e and tyrosinase-related protein 2 (Trp2) peptides (13). 85	
Immunization resulted in a significantly improved survival after lethal tumor 86	
challenge. A recent study also demonstrated TMV’s great potential to be used 87	
in stand-alone or prime-boost dendritic cell activation strategies (18).  88	
 89	
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In addition to utilizing TMV as a VLP to present surface epitopes, 90	
development has also proceeded with TMV coat protein encapsidated RNA 91	
vaccines. In previous experiments, we have produced and tested Semliki 92	
Forest virus (SFV) RNA encapsidated with TMV coat protein in vitro. 93	
Attenuated SFV was modified by insertion of a TMV origin of assembly to 94	
produce, in vitro, rod shaped virus particles that resembled TMV (21) by 95	
mixing SFV-Oa RNA with purified TMV coat protein. Vaccination with SFV-Oa 96	
encoding the model antigen beta-galactosidase (bGal) resulted in boosted 97	
antibody responses to bGal protein, demonstrating that TMV encapsidated 98	
RNA was translated and was antigenic in the absence of adjuvant, and, 99	
further, that the presence of the TMV Oa did not disrupt SFV replication 100	
functions. However, as a common phenomenon of pathogenic RNA virus 101	
vaccines (22), SFV-Oa RNA induced apoptosis in infected cells, which may 102	
limit duration of antigen exposure and reduce immune activation to transgene 103	
encoded antigens.  104	
 105	
To improve on our previous results with SFV, we applied TMV encapsidation 106	
to the RNA of the nonpathogenic insect virus, Flock House virus (FHV), which 107	
is capable of replicating in human cells. The advantages of FHV include a 108	
bipartite genome, where the polymerase is encoded by the independently 109	
replicating RNA 1 and the structural capsid gene is encoded by RNA 2, 110	
allowing for easy manipulation of the RNA1 genome for vaccine development 111	
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and the separation of replication from packaging. We have already tested in 112	
vitro assembled TMV-FHV particles and have shown that TMV Oa did not 113	
disrupt FHV viral replication, using an enhanced green fluorescent protein 114	
(eGFP) transgene to monitor replication and expression in mammalian cells 115	
(23). However, the limitations of in vitro encapsidation remain with this 116	
system; namely the cost of RNA synthesis and potentially reduced translation 117	
due to inefficient in vitro 5' capping. 118	
 119	
To overcome these limitations, we explored an in planta strategy for 120	
producing viral RNA in vivo. For the present study, we hypothesized that FHV 121	
RNA, which replicates well in mammalian (24) and plant cells (25) but is not a 122	
pathogen of either, could be encapsidated in planta if sufficient TMV coat 123	
protein were provided in trans. We further predicted that in planta produced 124	
nanoparticles would be able to express transgene after animal vaccination, 125	
and will be comparatively more immunogenic than in vitro nanoparticles due 126	
to natural 5' capping. As described in the following report, we used a 35S 127	
promoter to express FHV-eGFP-Oa RNA and the plant viral vector Foxtail 128	
mosaic virus (FoMV) to express TMV coat protein in quantities sufficient for 129	
encapsidation of FHV RNA in agroinoculated Nicotiana benthamiana plants. 130	
Replication of functional FHV-eGFP-Oa was observed as an unusually strong 131	
eGFP fluorescence, and near wild type levels of TMV-coat protein were 132	
produced by co-delivered FoMV vector. We observed virion particles of the 133	
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typical TMV morphology as a final product. When these nanoparticles were 134	
used to vaccinate mice, the expression of eGFP transgene was confirmed by 135	
an anti-eGFP immune response greater than that observed for in vitro 136	
encapsidated control particles. This is the first report of in planta 137	
transencapsidated nanoparticles and represents the first step towards 138	
producing a commercially viable vaccine of this type. 139	
 140	
MATERIALS AND METHODS 141	
Construction of T7/FHV-C2-GFP vector and expression in mammalian 142	
cells. The plasmid containing the FHV RNA1 expression cassette was kindly 143	
provided by Dr. A. Ball. It is a T7 promoter-driven plasmid containing the 144	
RNA1 portion of the FHV genome and was previously described (26). A 145	
polylinker, CTCGAGGCGATCGCCTGCAG, encompassing the 3 restriction 146	
sites XhoI, AsiSI and PstI, was cloned into one of four insertion sites: C1, nt. 147	
3034; C2, nt. 3037; C3, nt. 2731; and C4, nt. 3055, and confirmed by direct 148	
sequencing. Enhanced green fluorescent protein (eGFP) ORF was then 149	
cloned into these sites via XhoI and PstI to create T7/FHV-C-(1-4)-GFP 150	
constructs (Fig. 1A). To confirm stability of the eGFP modified FHV viral RNA, 151	
full-length RNA transcripts were generated from the T7/FHV-C-GFP DNA in 152	
vitro via a T7 promoter kit (mMESSAGE mMACHINETM, Ambion, TX). 2 µg 153	
RNA was used to transfect BHK-21 cells with DMRIE-C (Invitrogen, Carlsbad, 154	
CA). Transfected cells were incubated at 37°C for 4 hours, after which fresh 155	
	 8
growth media was used to replace transfection media. Cells were then placed 156	
at 28°C for 24 hours. Expression of fluorescence was confirmed using a 157	
Nikon Eclipse TS100 microscope and NIS-elements imaging software. Cells 158	
were observed for 2 days post-transfection.  159	
 160	
In planta expression vectors. In order to express FHV in plants, full-length 161	
FHV viral vector sequence was transferred from T7/FHV-C2-GFP (Fig. 1A) 162	
and placed between the StuI/XbaI sites of the plant binary vector JL22 (27) to 163	
create 35S/FHV-C2 (Fig. 2A). To allow Oa insertion, additional restriction 164	
sites were introduced on either side of the eGFP ORF by amplifying the eGFP 165	
ORF with an upstream primer containing XhoI/AscI and a downstream primer 166	
containing AvrII/PstI and then reinserting this product into 35S/FHV-C2 167	
between the XhoI and PstI sites. TMV Oa (95 bp: TMV nts. 5432-5527; (28) 168	
was inserted upstream or downstream of the eGFP ORF to create 169	
35S/FHVC2-o1 and -o2, respectively (Fig. 2A). PCR with a primer containing 170	
a mutated eGFP ORF stop codon was used to create 35S/FHVC2-o3.  171	
 172	
Several modifications were made to improve eGFP expression. T7/FHV-C4-173	
2sg was created to maintain B2 expression, by duplicating the 3’ end of FHV 174	
RNA1 (nt. 2518-3055) and inserting it after the eGFP open reading frame in 175	
T7/FHV-C4-GFP. 35S/FHV-C4-2sg (Fig. 2B) was generated by transferring 176	
the viral sequence into JL22 (27), as outlined above. To express both FHV B2 177	
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and eGFP separately, a 498 bp DNA segment was synthesized (gBlock, IDT, 178	
Coralville, IA) and inserted between the XhoI and PstI sites in 35S/FHV-C4. 179	
This segment contained a stop codon in the B2 ORF, 10 bp of the FHV 3' 180	
UTR for any potential required context for B2 ORF expression, the 95 bp TMV 181	
Oa, a repeat of the presumed B2 subgenomic promoter (FHV 2480-2809, 182	
including 69 bp past the B2 start) to drive eGFP expression, and a start codon 183	
and insertion sites for eGFP. To recreate a more FHV authentic 3' region 184	
following the eGFP ORF, the final 24 bases of B2 ORF was added 185	
downstream of the eGFP stop codon, to yield the final construct: 186	
35S/FHV2sg2 (Fig. 2B). All recombinant DNA methods and suppliers for the 187	
plant constructs were as previously described (29). 188	
 189	
Agroinoculation and visualization. Nicotiana benthamiana plants were 190	
grown and agroinoculated as previously described (29). Excised eGFP-191	
fluorescent leaves were visualized using a blue light Dark Reader (Clare 192	
Chemical, Dolores, CO, USA). The defective interfering construct 193	
DI638/wtGFP (30) was a gift from A. Rao (UC Riverside) and those 194	
inoculations were visualized with a hand held UVL-56 lamp (UVProducts, 195	
Upland, CA, USA).  196	
 197	
Relative fluorescence resulted by different FHV constructs was measure by 198	
grinding inoculated leaf tissue in 1X Phosphate Buffered Saline (PBS). The 199	
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collected supernatant was assessed on a microplate reader (Thermo 200	
Fluoroskan Ascent FL), with black 96 well plate (COSTAR 3925, Corning Inc. 201	
NY). Filter set of 485nm (excitation) and 538nm (emission) was used in order 202	
to detect eGFP fluorescence. 203	
 204	
Plant protoplasts. Protoplasts were prepared from N. benthamiana leaves 4 205	
days post-inoculation. Leaves were sliced into 2 mm strips and vacuum 206	
infiltrated with MMC buffer (13% mannitol, 5 mM MES, 10 mM CaCl2, pH 5.8) 207	
containing 1% Onozuka cellulase RS and 0.5% Macerase (both from 208	
Phytotechnology Labs, Shawnee Mission, KS, USA) and gently rocked 209	
overnight. Protoplasts were mounted in MMC on a glass slide. Images were 210	
obtained as previously described (29). 211	
 212	
Plant produced nanoparticles. To purify nanoparticles, agroinoculated N. 213	
benthamiana leaves, 4-7 days p.i., were ground in a mortar in extraction 214	
buffer (50 mM sodium acetate, 0.86 M NaCl (5% w/v), 0.04% sodium 215	
metabisulfite, pH 5.0). Crude homogenate was filtered through cheesecloth 216	
and 8% (v/v) n-butanol was added, and then incubated at room temperature 217	
for 15 min, and then centrifuged at 10,000 x g for 15 min. The supernatant 218	
was decanted through cheesecloth, and nanoparticles were precipitated with 219	
PEG 8000 (EMD Millipore, USA) at 4% on ice for 1 hr, followed by 220	
centrifugation at 10,000 x g for 10 min. The pellet was resuspended in a 221	
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minimum of 10 mM phosphate buffer (pH 7.2) and then centrifuged at 16,000 222	
x g for 10 min. The supernatant was collected and nanoparticles were purified 223	
with an additional round of PEG precipitation. The final nanoparticle pellet 224	
was suspended in 10mM phosphate buffer (pH 7.2) and stored at -20°C. 225	
Protein concentration was determined by bicinchoninic acid (BCA) assay 226	
(Pierce Biotechnology, Rockford, IL, USA).  227	
 228	
Transmission electron microscopy was used to visualize purified 229	
nanoparticles on a JEOL JSM 1010 microscope. A 3 µl drop of nanoparticles 230	
was adsorbed onto 300 mesh formvar coated grids (Electron Microscopy 231	
Sciences, PA, USA) for 1 minute, drawn off, and stained with 1% 232	
phosphotunstic acid (pH 7). Image was taken by XR16 TEM camera 233	
(Advanced Microscopy Techniques, MA, USA), and with AMT Image Capture 234	
Engine V602 (Advanced Microscopy Techniques, MA, USA), at 30,000X to 235	
40,000X magnification. 236	
 237	
In vitro nanoparticle assembly and vaccine preparation. SFV-eGFP or 238	
FHV-eGFP RNA was transcribed from T7 plasmids using a capped RNA 239	
synthesis kit (MmessageMachine; Ambion), quantitated by absorbance, and 240	
checked for integrity by gel electrophoresis. 50 µg of RNA was then incubated 241	
with 1.4 mg of TMV coat protein, prepared by a modified protocol as 242	
previously described (21). Briefly, encapsidations were carried out using 243	
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overnight incubation in a 0.05 M phosphate buffer (pH7) at room temperature. 244	
Particles were recovered by PEG precipitation and quantitated by BCA assay 245	
(BioRad, CA).  246	
 247	
Vaccination and immune response evaluation in mice. BALB/c mice 248	
(Charles River, CA) were housed at Touro University according to guidelines 249	
established in the Care and Use of Animals, and performed according to 250	
IACUC approved protocols. Typically, 3 mice were given a 100 – 200 µl 251	
subcutaneuous (s.c.) injection of 15 or 30 μg encapsidated product, or 15 µg 252	
eGFP protein as a positive control (Vector Labs), or PBS as a negative 253	
control. Vaccines were typically administered at two-week intervals and tail 254	
vein bleeds were taken at 10 days after vaccines 2 and 3 for enzyme linked 255	
immunosorbent assay (ELISA) analysis.  256	
 257	
The IgG immune response was determined by ELISA. 96-well microtiter 258	
plates (MaxiSorp; Nalge Nunc) were coated with 5 µg/ml eGFP protein 259	
(Vector Labs) in 50 mM carbonate/bicarbonate buffer (pH 9.6). After blocking 260	
with 2% bovine serum albumin (BSA) in PBS, serial dilutions of the sera were 261	
added for one hour, the plates were washed and incubated for an additional 262	
hour with anti-mouse IgG Horse Radish Peroxidase (HRP) conjugated 263	
secondary antibody (Southern Biotech) in PBS+BSA. Plates were developed 264	
using a tetramethyl benzidine substrate solution (TMB; BioFx) and the 265	
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reactions were stopped by the addition of 1N sulfuric acid. Plate absorbance 266	
was read at 450 nm in a 96-well plate spectrophotometer (Molecular 267	
Devices). Relative anti-eGFP titers reported were determined from a standard 268	
curve generated by a 3-fold serial dilution of a 100 ng/ml rabbit anti-eGFP 269	
polyclonal antibody (Sigma) detected with an anti-Rabbit-HRP secondary. 270	
Statistical analysis was carried out using Prism software (GraphPad), using 271	
unpaired t-test with Welch's correction.  272	
 273	
RESULTS 274	
FHV vector expression in mammalian cells. FHV vectors were designed 275	
and tested for the expression of eGFP in BHK-21 cells. A cassette containing 276	
three restriction sites (XhoI, AsiI and PstI) was placed at the FHV C2 site (31); 277	
namely, immediately downstream of the polymerase/B1 stop codon, which is 278	
also six codons upstream from, and in phase with, the B2 stop codon (Fig. 279	
1A). This FHV-C2 construct thus expresses a B2-eGFP-B2 fusion, with 99 280	
amino acids of B2 upstream of eGFP and 6 amino acids of B2 at the C 281	
terminus. Insertion at a second eGFP ORF insertion site, the C4 site, would 282	
produce the full B2 protein fused to the eGFP (Fig. 1A). eGFP expression 283	
was observed in mammalian cells (Fig. 1B) within 24 hours post transfection. 284	
Expression with both constructs peaked at 48 hours and was maintained until 285	
72 hours, with approximately 15-20% transfection efficiency. Fluorescence 286	
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began to decrease after 72 hours and gradually diminished over time. The C4 287	
insertion construct gave reduced fluorescence compared to C2 (Fig. 1B).  288	
 289	
Strong FHV/eGFP expression in N. benthamiana after p19 co-290	
agroinoculation. The 35S/FHV-C2-GFP and 35S/FHV-C4-2sg constructs 291	
were made by transferring viral sequences from the mammalian vectors into 292	
plant binary vector pJL22 (27) between a cauliflower mosaic virus 35S 293	
promoter and 35S terminator (Fig. 2). Leaves agroinoculated with these 294	
constructs gave a weak fluorescence (Fig. 3), as did leaves inoculated with 295	
the positive FHV/wtGFP control, F1DI, comprising FHV RNA1 and DI638, the 296	
defective interfering RNA of FHV RNA2, carrying wtGFP (30). However, when 297	
the silencing suppressor, p19 (32), was provided by co-agroinoculation, a 298	
much stronger fluorescence was observed (Fig. 3) which was much stronger 299	
than the F1DI + p19 control. Subsequently, p19 was included in all 300	
inoculations. 301	
 302	
To create a FHV vector competent for encapsidation by TMV CP, the TMV 303	
Oa was inserted into 35S/FHV-C2-GFP at two different positions (35S/FHV-304	
C2-o1, o2), and adjacent to eGFP ORF. In order to test the influence of C 305	
terminal TMV Oa fusion on eGFP expression, a third construct, 35S/FHV-C2-306	
o3, was designed with the introduction of a stop codon at the natural stop site 307	
of eGFP, resulting in an eGFP fusion with B2 only at the N terminus. These 308	
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three Oa containing constructs (35S/FHV-C2-o1 to o3) were found to express 309	
only slightly less eGFP in leaves than the non-Oa, 35S/FHV-C2 (Fig. 3 and 310	
Fig. 4A). This was unexpected since the TMV Oa sequence was added close 311	
to either the putative sub-genomic promoter or the FHV 3’UTR. Little 312	
difference in fluorescence was observed between the three Oa containing 313	
constructs. 314	
  315	
To express the FHV silencing suppressor, B2 (Albariño et al., 2003), in 316	
conjunction with eGFP, we made variants of 35S/FHV-C4-2sg. To prevent the 317	
deletion of the eGFP ORF, we placed the eGFP ORF at the 3' terminus of the 318	
virus, in contrast to the C4-2sg construct. Any homologous recombination 319	
between the two homologous subgenomic regions would delete B2 and Oa, 320	
but not eGFP, and deletion mutants would not be packaged as nanoparticles. 321	
It was observed that the 35S/FHV-C2-GFP construct clearly resulted in a 322	
brighter fluorescence than 35S/FHV-C4-2sg, which was further confirmed by 323	
fluorometry analysis (Fig. 4A).  324	
 325	
To explore the impact of improved B2 expression, a portion of the FHV 3' 326	
UTR, which is normally downstream of the B2 ORF, was added to the internal 327	
B2 ORF followed by the TMV Oa. The final construct 35S/FHV2sg2 was 328	
created by adding 24 bp of C-terminal B2 sequence to aid eGFP expression 329	
by providing more natural context at the 3' end of the ORF. We expected to 330	
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see stronger eGFP expression and/or FHV B2 expression that would 331	
functionally replace p19. However, the FHV2sg2 vector did not significantly 332	
improve eGFP fluorescence expression compared with the original C4-2sg 333	
construct in planta (Fig. 3). Other constructs were built and tested, which 334	
included the precedent construct of FHV2sg2 (data not included) and a vector 335	
with the addition of strong Kozak context in pursuit of enhanced expression 336	
(FHV2sg2KSS, supplementary Fig 1a). Neither resulted any improvement in 337	
eGFP fluorescence (Fig 3). In all cases, p19 was still required via co-338	
agroinoculation for strong fluorescence. All subsequent experiments used the 339	
35S/FHV-C2-o3 construct co-agroinoculated with p19.  340	
 341	
Co-expression of FHV and FECT in plants 342	
To encapsidate FHV vector RNA in planta, a ratio of 20:1 mass ratio of TMV 343	
coat protein (CP) to RNA is required. The high expression Foxtail mosaic 344	
virus vector, FECT (29), was used to produce TMV CP without being itself 345	
encapsidated. FECT produced TMV CP at a level comparable to the TMV 346	
vector JL24 (27), which expresses TMV CP as a native gene (Fig. 5).  347	
 348	
We next examined the ability of FHV and FECT to co-infect cells, to ensure 349	
there was no replication interference. In a co-infection test system, 35S/FHV-350	
C2 expressing eGFP and FECT expressing DsRed were co-agroinoculated 351	
into several leaves, resulting in a yellow-green fluorescence under blue light 352	
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when viewed without magnification (Fig. 6A). In order to determine co-353	
infection of single cells, co-infected leaves were reduced to protoplasts and 354	
the protoplasts were examined under a UV microscope. As seen in a 355	
representative photo (Fig. 6B), about 75% of the eGFP positive cells are also 356	
DsRed positive, but not vice versa. FECT strongly infects the great majority of 357	
plant cells (29), as seen by the DsRed signals in Fig. 6B. FHV/eGFP is an 358	
insect virus construct and infects a much smaller number of plant cells, but 359	
those that are infected are mostly co-infected with FECT/DsRed, 360	
demonstrating the high frequency at which double infection occurs with this 361	
system, given the limitations of FHV infectivity itself. 362	
 363	
eGFP expression by FHV enhanced by delayed TMV CP expression 364	
Nanoparticles were produced by agro-inoculation with 35S/p19, 35S/ FHV-365	
C2-o3, and 35S/FECT-TMVCP. The average size of our FHV-C2-o3 366	
nanoparticles is estimated to be ~200nM based on the length of the FHV RNA 367	
genome (C2-o3; 4182 nts.), compared with wide type TMV (6395 nts.) that 368	
generates a 300nM particle (Fig. 7).  369	
 370	
In all experiments, the presence of TMV CP at the time of FHV early infection 371	
(i.e., co-inoculation) led to reduced eGFP fluorescence. We hypothesized that 372	
CP binding the Oa early in infection impeded the replicative or translational 373	
events of FHV RNA. To test this, a “2-step” protocol was used in which the 374	
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FECT/TMV CP inoculation was delivered three days after the FHV/GFP/Oa 375	
and p19 inoculations. The 2-step procedure consistently increased eGFP 376	
expression (Fig. 4). 377	
 378	
Immune response to nanoparticles in mice 379	
In order to test the capacity of transencapsidated FHV RNA to express the 380	
eGFP transgene in mice, in planta transencapsidated FHV RNA was used to 381	
immunize BALB/c mice with in vitro transencapsidated FHV RNA or SFV RNA 382	
as encapsidation controls. Two doses of 15 μg or 30 μg encapsidated RNA 383	
(0.75 or 1.5 μg of RNA, respectively) were given by subcutaneous injection, 384	
without adjuvant. eGFP protein (15 μg) was used as a positive control while 385	
PBS buffer was used as a negative control. Sera collected from mice before 386	
immunization and after a single dose were essentially negative for immune 387	
responses for all groups (data not shown). Weak but detectable anti-eGFP 388	
IgG responses were measured by ELISA after a second vaccination (pV2, 389	
Fig. 8), but all groups were statistically similar to PBS, including eGFP protein 390	
immunization. After a third immunization (pV3), all groups showed a strong 391	
trend toward augmented immunity against eGFP, but in large part were not 392	
significantly different than PBS, mainly due to high variance between 393	
responders and small group size. However, the highest dose of in planta 394	
encapsidated FHV (C2-o3, 30µg) and eGFP protein control had IgG titers 395	
significantly higher than all in vitro encapsidated viral vector treatments. This 396	
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confirmed the successful expression of eGFP transgene by 397	
transencapsidated FHV RNA, after uptake and presumed co-translational 398	
disassembly of TMV coat protein. This is notable, in light of low replication 399	
ability of FHV RdRp in animal cells at 37 degree (33). 400	
 401	
Discussion 402	
We have shown in this study that FHV can be encapsidated in planta with 403	
TMV coat protein and the resulting nanoparticle vaccines had improved 404	
characteristics compared to in vitro encapsidated FHV RNA. In previous 405	
studies, we demonstrated that SFV could be encapsidated in vitro with TMV 406	
coat protein (21). TMV coat protein produced in vivo had also been used to 407	
assemble wild type TMV virions in E. coli (34) and mRNAs had been 408	
encapsidated in planta to form TMV hybrid virions (35). As well, Brome 409	
mosaic virus (BMV) RNA containing the TMV Oa was transencapsidated with 410	
TMV CP in barley protoplasts (36) and Rao and colleagues produced non-411	
specific transencapsidated virions by coat protein of the similarly structured 412	
BMV in studying encapsidation specificity (37). Though FHV virions use a 413	
multitude of molecular cues in virion assembly, similar to other icosahedral 414	
viruses (38), TMV and other tobamoviruses utilize a single Oa sequence to 415	
initiate assembly, with the remainder of the encapsidated sequence 416	
apparently without further molecular cues (39). Thus, any RNA containing the 417	
TMV Oa should be able to be transencapsidated. It may be possible to extend 418	
	 20
this technique to other viral species for viral-vectored nanoparticle vaccine 419	
assembly in planta.  420	
 421	
The individual components of the nanoparticles appeared to be produced at 422	
high levels. The FECT viral vector produced TMV CP at the same level as the 423	
native TMV vector, JL24(Fig 5). FHV vector levels, as measured by visually 424	
assessed fluorescence of eGFP (Fig. 3), were greater in side by side studies 425	
than the DI638 vector used in previous FHV work in N. benthamiana (37). 426	
The coexpression of p19 silencing suppressor further boosted this eGFP 427	
expression even with FHV vector constructs that had an intact B2 silencing 428	
suppressor (Fig.2 and 3).  429	
 430	
As a prerequisite for assembly, coexpression of both vectors in a single cell is 431	
necessary. The FECT vector was shown to express in the majority of cells 432	
harboring the FHV vector (Fig. 6). However, when FHV RNA and TMV CP 433	
vectors were co-inoculated, we saw a significant decrease in fluorescence. A 434	
supplementary experiment was performed in order to exclude the possibility 435	
of FECT interfering FHV replication (suppl. Fig. 2). This inhibition 436	
phenomenon is most likely mediated by classical coat protein resistance (40) 437	
and was previously observed by the Ahlquist group working with BMV 438	
transencapsidated by TMV CP. BMV RNAs 1 and 2 containing the TMV Oa 439	
decreased in replication 20-fold when co-inoculated with BMV RNA 3 440	
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expressing TMV CP (36). This was theorized to be due to TMV CP binding to 441	
the BMV RNAs and interfering with replication. We investigated this 442	
hypothesis by separating the agroinoculation of FHV vector and TMV CP into 443	
two steps, delaying the expression of TMV CP until FHV RNA replication was 444	
sufficient to generate robust eGFP protein. The two-step plants consistently 445	
showed higher expression of the viral eGFP transgene (Fig. 4), suggesting 446	
RNA packaging by TMV CP reduced FHV RNA replication and/or translation.  447	
  448	
Several modifications were made in an attempt to improve FHV vector 449	
replication in plants. The addition of TMV Oa led to strong inhibition of BMV 450	
RNA replication even in the absence of TMV CP in a previous study (36). 451	
However, we observed only a slight decrease in eGFP production by the FHV 452	
vectors carrying Oa. C2 constructs carrying Oa at two different sites (C2-o1 453	
and C2-o2) did not differ significantly in eGFP fluorescence produced. 454	
Recreating a native C-terminus for eGFP (C2-o3) also had no effect. 455	
Constructs with unmodified B2 silencing suppressor ORFs (2sg2 series) were 456	
less effective than the C2 series with the B2 ORF fused to eGFP. These were 457	
longer constructs, but the shorter C4 construct was also less fluorescent in 458	
mammalian cells than the C2 construct (Fig. 1B), suggesting the common C4 459	
insertion site as detrimental. Ultimately, the inclusion of p19 as a co-inoculant 460	
was the sole factor in achieving high eGFP expression in plants from the FHV 461	
vectors, re-confirming the importance of mitigating RNA silencing in planta. 462	
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 463	
It is possible that the size of the duplicated subgenomic promoter in the 2sg2 464	
series was insufficient since a longer FHV subgenomic promoter segment 465	
was found more efficacious in a previous study (41). Beyond the core nts. 466	
2518-2777, the region from nt. 2302-2518 may serve as an important 467	
enhancer (42). Polarity preference was found on FHV (41) and other positive-468	
strand RNA viruses; specifically, that two pieces of sgRNA were replicated at 469	
different levels, with the longer one (closer to replicase) being dominant. This 470	
may explain why we see more eGFP fluorescence in the 35S/ FHV-C4-2sg, 471	
which has the eGFP ORF included in the first sgRNA3, than–FHV-2sg2 472	
series, which have eGFP ORF included in the second sgRNA3.  473	
 474	
In order to verify the capacity of these transencapsidated nanoparticles to 475	
express transgene in animal cells, FHV C2-o3 encapsidated particles were 476	
used as a vaccine, and an IgG antibody response to eGFP was measured 477	
(Fig. 8). Despite the reported deficiency of FHV replicase to function well in 478	
37 degree (33), a titer of anti-eGFP antibody equal to that of 15ug eGFP 479	
protein was observed after three injections with 30 ug of FHV C2-o3 480	
nanoparticles (1.5ug FHV RNA). This demonstrated delivery and expression 481	
of the eGFP transgene and suggested a considerable boosting of the immune 482	
response by RNA antigen delivery. In vitro FHV and SFV/TMV CP 483	
nanoparticles produced a significantly lower immune response in this study, 484	
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possibly due to lower percentage of 5' capping, which is known to affect 485	
translation efficiency.  486	
 487	
During nanoparticle in planta assembly, FHV subgenomic RNA3 may also be 488	
encapsidated by TMV coat proteins, co-purified and be represented in mice 489	
injections. The possibility of sgRNA3 being used as mRNA templates has 490	
been considered, since sgRNA3 also contains eGFP sequence and contains 491	
a TMV 0a. However, from the numerous TEM images, it is apparent that the 492	
amount of sgRNA3 nanoparticles (~67nM) is not evident or a minority of the 493	
particles,  and the majority nanoparticles are of full length (200nm) . 494	
Furthermore, from the previous literature, the non-replicating mRNA 495	
vaccination strategy has largely relied on extensive chemical modifications, 496	
additional use of adjuvants (43), and an ex vivo route to transinfect dendritic 497	
cells(44). In two studies using eGFP mRNA to transinfect dendritic cells, 498	
eGFP either degraded too rapidly due to the lack of  additional targeting 499	
signals(46), or was expressed well in dendritic cells but failed to trigger 500	
dendritic cell maturation without using inducing agents(47). Overall, it is more 501	
likely that a functional replicase and a self-replicating viral RNA account for 502	
the bulk of the immune stimulation observed in this work, rather than 503	
translation from sgRNA3.   504	
 505	
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Several improvements can be made to the utility of TMV coat encapsidated 506	
RNA. In order to increase immune activation and greater CD4 T cell 507	
response, future optimization may include the use of other viruses with a 508	
replicase active at 37 degree, such as Nodamura virus (33). Peptide directed 509	
endosomal escape of nanoparticles (48-50) may also increase animal cell co-510	
translational disassembly, and subsequent protein accumulation. In our study, 511	
eGFP was used to track viral expression of eGFP in plant and animal cells. 512	
Expression of a more potent immunogen (e.g., ovalbumin) with better 513	
characterized antigenicity should also improve measurement of both antibody 514	
and T cell immunogenicity after nanoparticle vaccination.  515	
 516	
In conclusion, we were able to produce FHV RNA and TMV CP, in the same 517	
plant cell, resulting in assembly of rod shaped packaged RNA. These in 518	
planta produced nanoparticles were shown to induce an antigen-specific 519	
immunogenicity exceeding that of in vitro packaged RNA nanoparticles. Our 520	
next tasks are to investigate cellular localization of FHV RNA and TMV CP 521	
and to optimize heterologous virion assembly. We will also seek to target the 522	
hybrid virion nanoparticles to the correct compartment in the mammalian cell 523	
in order to facilitate TMV-CP virion disassembly and improved RNA 1 524	
replication. Completion of these goals will answer basic virological questions 525	
of component trafficking, disassembly and replication in the process of 526	
optimizing vaccine production and potency.  527	
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 703	
Figure Legends 704	
FIG 1 FHV viral vector constructs for expression in mammalian cells. (A) Two 705	
constructs, C2 and C4, differing in the insertion site for eGFP. B2, FHV 706	
silencing suppressor; Rbz, HDV ribozyme for precise viral RNA 3' end 707	
excision. (B) Expression of T7/FHV-C2-GFP (left) and T7/FHV-C4-GFP (right) 708	
in BHK21 cells. 709	
 710	
FIG 2 FHV viral vector constructs for expression in plants. The C2 and C4 711	
constructs from Figure 1 were provided with the 35S plant expression 712	
promoter and the TMV origin of assembly (Oa) to allow for encapsidation. (A) 713	
In the C2 series, TMV-Oa was added at different positions in C2-o1, and -o2, 714	
and in -o3 the eGFP native C terminal stop codon was preserved. B2’ stands 715	
for the B2 ORF C-terminal remaining after eGFP insertion. (B) The C4-2sg 716	
has a duplicated subgenomic promoter to express unfused versions of eGFP 717	
and B2 silencing suppressor. The eGFP ORF is between the duplicated 718	
	 30
subgenomic promoters in C4-2sg, but follows the final subgenomic promoter 719	
in 2sg2 construct. The 2sg2 constructs retain the B2 C-terminus (B2’’) 720	
following the eGFP ORF to mimic the 3' end of the native FHV. (C) The 721	
FECT/TMVCP construct and the JL6/p19 were used as co-agroinoculants 722	
and provided coat protein and silencing suppressor, respectively.  723	
 724	
FIG 3 eGFP expression from constructs from Figure 2. Agroinoculated leaves 725	
of Nicotiana benthamiana were examined, 7 dpi, under blue light with visible 726	
light to outline leaf shape. 35S/FHV-C2 inoculated alone or with p19 silencing 727	
suppressor. FECT-eGFP is general high expression positive control. F1DI (+/- 728	
p19) is a positive control for FHV/GFP expression and comprises FHV RNA1 729	
plus a defective interfering construct of RNA2. All other inoculations included 730	
p19 unless otherwise mentioned. 2sg2KSS construct is included in the 731	
supplementary data. All other designations as in Figure 2. 732	
 733	
FIG 4 eGFP expression in plants by FHV constructs and in 1-step and 2-step 734	
inoculation procedures. (A) eGFP fluorometry of N. benthamiana 735	
agroinoculated with various FHV constructs. p19, mock inoculation with p19 736	
only; FECT-eGFP, high expression positive control; 1-step and 2-step, co-737	
agroinoculation or delayed TMVCP agroinoculation. Four replicates each 738	
treatment, except 15 replicates for 1-step and 2-step treatments. (B) eGFP 739	
	 31
expression compared in 1-step and 2-step agroinoculation procedures. FHV-740	
C2-o3 without any FECT-TMV was also inoculated as a control. 741	
 742	
FIG 5 Expression of TMV CP by FECT plant viral vector. Lane a, FECT 743	
expressing TMV CP; Lane b, TMV vector JL24 (23) expressing CP and 744	
eGFP. Both agroinoculations in N. benthamiana included p19 silencing 745	
suppressor. Far left lane: protein marker (NEB # P7708) with sizes in kDa 746	
indicated. 747	
 748	
FIG 6 Co-infection of plant cells by FHV and FECT viral vectors. (A) N. 749	
benthamiana plants were agroinoculated with p19 plus (left to right) 750	
35S/FHVC2-o3/GFP, FECT/DsRed or both vectors. (B) Protoplasts made 751	
from 4 dpi leaves coagroinoculated with FHV-eGFP/FECT-DsRed (right leaf 752	
in (A)) were visualized for eGFP and DsRed fluorescence, showing the 753	
majority of the FHV-eGFP infected cells were also infected with FECT.  754	
 755	
FIG 7 TEM of in vitro and in planta produced nanoparticles. (A) In vitro 756	
assembled FHVOa. (B) In vitro assembled SFVOa (C) in planta assembled 757	
FHV-C2-o3 (CP provided by FECT/TMVCP). 100 nm bars indicated. 758	
 759	
FIG 8 In vivo analysis of FHV vaccine potency. Balb/C Mice (n = 3) were 760	
vaccinated 3 times, two weeks apart with indicated amounts (15 or 30 µg 761	
	 32
protein) of TMV encapsidated FHV-eGFP, produced either in vitro by mixing 762	
RNA and coat protein, or in planta by co-expression of RNA and coat protein 763	
after agroinfiltration. PBS was used as a negative control, and in vitro 764	
encapsidated SFV-eGFP or 15ug of eGFP protein was used as a positive 765	
control. ELISA analysis was used to determine anti-eGFP IgG titers on sera 766	
collected at 10 d after either vaccine 2 (pV2) or after vaccine 3 (pV3). Titers 767	
were measured against a known quantity of anti-eGFP standard (Vector 768	
labs), and shown as mean +/- SEM using GraphPad Prism. Statistical 769	
analysis of differences between PBS and vaccine groups after vaccine 3 was 770	
evaluated by one-tailed t-test. The asterisk indicates statistically significant 771	
difference from PBS control. 772	
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Suppl. Fig 1:  In seek to further aid eGFP expression, a 35S/FHV‐2sg2KSS 
construct was built, in which the B1 and B2 start codons were knocked out 
and an ATG with strong Kozak context (CCACC ATG) was placed at the start 
of the eGFP ORF, resulting in an eGFP/B2 fusion with only a short B2 portion 
C‐terminal to the eGFP.
Suppl. Fig 2: In order to determine 
whether FECT virus will interfere with FHV             
replication in planta, FHVC2/GFP lacking 
the Oa sequence was co‐inoculated with 
FECT‐TCP and compared with FHVC2/GFP 
in the absence of FECT‐TCP. Fluorescence 
i il i th (l ft)was s m ar  n  e presence  e  or 
absence (right) of FECT coinfection. This 
confirmed the reduction of fluorescence by 
coinfection with FHVC2/GFP containing the 
TMV Oa and FECT‐TCP expressing coat 
protein is due to the hypothesized classical 
coat protein resistance.  All experiments 
were carried out with p19 co‐inoculation
FHV C2 onlyFHV C2 + FECT TCP
